An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Roche

Status: Completed

Conditions: Pancreatic Cancer

Treatments: Drug: gemcitabine; Drug: erlotinib

Study type: Observational

Funder types: Industry

Identifiers

NCT01782690

ML23024

Details and patient eligibility

About

This observational study will evaluate the impact of rash on survival of patients with metastatic pancreatic cancer treated with erlotinib plus gemcitabine. Further, clinical effectiveness, efficacy and safety will be assessed. Data will be collected for 12 months.

Enrollment: 338 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults, age >= 18 years
• Patients with metastatic pancreatic cancer where investigators have decided to give combination therapy of erlotinib and gemcitabine according to Summary of Product Characteristics (SmPC)

Exclusion criteria

• Contraindications for erlotinib according to Summary of Products Characteristics (SmPC)

Trial design

338 participants in 1 patient group

Erlotinib plus Gemcitabine

Description:

Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.

Treatment:

Drug: gemcitabine

Drug: erlotinib